Zhang X - Search Results

1

Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism.

Zhang M, Liu Q, Zhang M, Cao C, Liu X, Zhang M, Li G, Xu C, Zhang X. Zhang M, et al. Among authors: zhang x. J Nanobiotechnology. 2020 Nov 7;18(1):161. doi: 10.1186/s12951-020-00720-4. J Nanobiotechnology. 2020. PMID: 33160373 Free PMC article.

2

[Preparation and in vitro targeting of follicle stimulating hormone polypeptide modified nanoparticles].

Zhang XY, Chen J, Gao XL, Sun H, Xu CJ. Zhang XY, et al. Zhonghua Fu Chan Ke Za Zhi. 2008 Jul;43(7):533-7. Zhonghua Fu Chan Ke Za Zhi. 2008. PMID: 19080519 Chinese.

3

The piggyBac transposon is an integrating non-viral gene transfer vector that enhances the efficiency of GDEPT.

Kang Y, Zhang XY, Jiang W, Wu CQ, Chen CM, Gu JR, Zheng YF, Xu CJ. Kang Y, et al. Cell Biol Int. 2009 Apr;33(4):509-15. doi: 10.1016/j.cellbi.2009.01.017. Cell Biol Int. 2009. PMID: 19353779

4

Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo.

Zhang XY, Chen J, Zheng YF, Gao XL, Kang Y, Liu JC, Cheng MJ, Sun H, Xu CJ. Zhang XY, et al. Cancer Res. 2009 Aug 15;69(16):6506-14. doi: 10.1158/0008-5472.CAN-08-4721. Epub 2009 Jul 28. Cancer Res. 2009. PMID: 19638590

5

[Long-term and stable expression of transgene mediated by piggyBac transposon in gynecological malignant tumor cells].

Kang Y, Sun QW, Yu WB, Cheng MJ, Zhang XY, Wu X, Chen CM, Zheng YF, Xu CJ. Kang Y, et al. Among authors: zhang xy. Zhonghua Fu Chan Ke Za Zhi. 2010 Apr;45(4):292-7. Zhonghua Fu Chan Ke Za Zhi. 2010. PMID: 20646543 Chinese.

6

Altered protein expression in serum from endometrial hyperplasia and carcinoma patients.

Wang YS, Cao R, Jin H, Huang YP, Zhang XY, Cong Q, He YF, Xu CJ. Wang YS, et al. J Hematol Oncol. 2011 Apr 14;4:15. doi: 10.1186/1756-8722-4-15. J Hematol Oncol. 2011. PMID: 21489304 Free PMC article.

7

Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications.

Jie XX, Zhang XY, Xu CJ. Jie XX, et al. Oncotarget. 2017 May 26;8(46):81558-81571. doi: 10.18632/oncotarget.18277. eCollection 2017 Oct 6. Oncotarget. 2017. PMID: 29113414 Free PMC article. Review.

8

Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.

Zhang XY, Zhang M, Cong Q, Zhang MX, Zhang MY, Lu YY, Xu CJ. Zhang XY, et al. Int J Biochem Cell Biol. 2018 Feb;95:9-16. doi: 10.1016/j.biocel.2017.12.010. Epub 2017 Dec 13. Int J Biochem Cell Biol. 2018. PMID: 29247711

9

Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer.

Hong SS, Zhang MX, Zhang M, Yu Y, Chen J, Zhang XY, Xu CJ. Hong SS, et al. Drug Deliv. 2018 Nov;25(1):576-584. doi: 10.1080/10717544.2018.1440667. Epub 2018 Feb 20. Drug Deliv. 2018. PMID: 29461120 Free PMC article.

10

Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.

Zhang MX, Hong SS, Cai QQ, Zhang M, Chen J, Zhang XY, Xu CJ. Zhang MX, et al. Drug Deliv. 2018 Nov;25(1):797-806. doi: 10.1080/10717544.2018.1451934. Drug Deliv. 2018. PMID: 29542355 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184,268 results

Search Page

Filters